A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
Morning Overview on MSN
New method could mass-produce cancer-fighting natural killer cells
Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of ...
Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy study conducted in the continent of Africa Complete ...
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy most frequently involving the nasal cavity and upper aerodigestive tract, although it may present in other extranodal ...
The first clinical program to go over involves the use of ImmunityBio's CAR-NK cell therapy CD19 t-haNK, which is being tested in the ongoing phase 1 QUILT 106 study. As I alluded to above, the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback